20170425 BMS-Clinical Collaboration Release Transgene-FINAL
Category: dates
SillaJen and Transgene Announce the Enrollment of the First European Patient in Multinational Phase 3 Trial for Pexa-Vec in Advanced Liver Cancer
20170424 PR PHOCUS FPI EU – EN
Marie Landel and Maya Said Nominated to be Independent Members of Transgene’s Board of Directors
20170419 TG Appointments Board EN
Transgene and Institut Bergonié Start the Phase 2 Part of the METROmaJX Trial
20170412 PR Metro-JX Ph2 EN
Transgene Announces Upcoming Investor Meetings and R&D Day
20170410 PR Next investor events
Local and Abscopal Effects in Oncolytic Virotherapy are boosted by Immune Checkpoint Blockade, Immunogenic Chemotherapy, or IFNAR blockade
Laetitia Fend, et al. AACR, American Association for cancer Research, April 2017 Download the poster here Poster Presentation
In situ Biomarker analysis in cancer Immunotherapy: development of quantitative multiplex IHC
Sandrine Cochin, et al. CLARA, Forum de la recherche en cancérologie, April 2017 Download the poster here Poster Presentation
Transgene Presents Very Promising New Immunology Data of its Next Generation Armed Oncolytic Virus at the AACR Annual Meeting in Washington, DC
20170330-AACR poster EN
Major achievements in 2016 validate Transgene’s strategy and provide promising outlook for 2017
20170320 2016 Resultats annuels EN
First Patient dosed in Phase 2 Trial Evaluating Transgene’s TG4010 in Combination with Opdivo® (nivolumab) for 2nd Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC)
20170313 FPI Kelly study EN